INVESTMENT OBJECTIVE

To achieve capital appreciation on an absolute and relative basis over the medium to long-term horizon through investment in Swiss equities with a focus on innovative companies that are leaders in their markets profile.

PORTFOLIO REVIEW

February was punctuated not only by Donald Trump's boisterous announcements and their potential impact on the global economy, but also by a number of company annual earnings releases. Beyond the numbers reported, what matters more at this time of year is the guidance provided for the current fiscal period, allowing analysts to adapt their estimates. Unsurprisingly, against a backdrop that has never been so fluid and unclear, extreme caution prevails. At this point in time, favourable developments (resumption of investment in Germany, equitable resolution of the conflict in Ukraine) and unfavourable events (trade tariffs in Europe, inflation resurgence) could profoundly reshuffle the cards. As such, it is not surprising that investors have been favouring large caps and defensive sectors.


The Protea BAM Swiss Equities fund gained 0.6% during the month, bringing its year-to-date performance to 8.8%

The strongest absolute contributions were generated by Nestlé (+12%), Roche (+5%), Basilea (+16%), Zurich (+7%) and Richemont (+4%).

Conversely, the main detractors from performance were Belimo (-9%), Sandoz (-9%), Burckhardt Compression (-10%), Swissquote (-8%) and Straumann (-6%).

Early in the month, we sold our stake in Accelleron, considering its upside potential to have become limited, and increased exposure to Nestlé. Indeed, ahead of the food giant's earnings release, it seemed to us that its share price stood at an attractive level, after three years of almost uninterrupted decline (-40% between the January 2022 high and the January 2025 low, vs. -4% for the SPI). The Q4 and full-year 2024 results came in slightly above consensus expectations and thus reassured a market that had feared the business model was faltering. In fact, last quarter saw volume growth re-accelerate, enabling the Vevey-based giant to close the year with organic growth of 2.2%. For 2025, Nestlé is forecasting a gradual improvement, albeit with a still somewhat weak first quarter, thanks to an improvement in overall consumer sentiment, the launch of new products, particularly in the coffee and pet food sector, as well as the end of the negative impact coming from retailer destocking and the boycott of Western brands in the Middle East. The new CEO, in place since last summer, has admitted that the group placed too much emphasis during recent years on mergers & acquisitions and the nutrition, health and wellness (NHS) division, to the detriment of the more resilient key segments. Although some patience will be required before Nestlé returns to the growth rates of the past, the outlook is better, and the excessively negative market sentiment has turned.

NET PERFORMANCE AND ANNUAL PERFORMANCE IN CHF



		MSCI		
	Switzerland			
	Fund	10-40	+/-	
1 Month	0.6%	1.7%	-1.2%	
3 Months	7.5%	9.1%	-1.5%	
YTD	8.8%	10.3%	-1.5%	
Since inception	3.9%	16.4%	-12.5%	

Source: All data and graphs throughout the document from Bruellan.

Past performance may not be a reliable guide to future performance. All forms of investment involve risk. The benchmark index is the MSCI Switzerland 10-40.

Please refer to the end of the document mentioned for performance comparison purposes.

RISK & REWARD



Inception date 10 June 2021 CHF Currency Anick Baud Lead Manager

Florian Marini CFA, CMT Co-Manager Fund size* CHF 31 Millions

Liquidity (sub./red.) Daily

Min. Investment Instit.: 1 million CHF

0.0% / 0.0% Entry/exit fees Management fees 0.8% 20% Performance fees High Water Mark

Benchmark MSCI Switzerland 10-40 ISIN Instit.: LU2264701074

Instit.: PRPSEIC LX Bloomberg


NAV Instit: 103.95

Not all the costs are presented, further information can be found in the

STATISTICS

	Fund	MSCI Switzerland 10-40
Leading PE	24.2	17.4
EV/EBITDA	18.6	12.2
P/Book	5.6	1.7
Dividend Yield	1.9%	2.8%
ROE	22.9%	9.7%
Debt/Equity	56.6%	58.2%
Interest Coverage	14.8	8.1
Beta	1.0	1.0
Volatility	17.3%	13.5%

ALLOCATION BY MARKET CAP




^{*} the total strategy size is CHF 66 millions

PROTEA BAM SWISS EQUITIES

FEBRUARY 2025



ALLOCATION BY SECTOR



■ Portfolio ■ Benchmark

FUND COMPLEMENTARY DETAILS

Administrator Representative in Switzerland Investment Manager Paying agent in Switzerland Auditor Custodian Fund Partner Solutions SA FundPartner Solutions (Suisse) SA Bruellan SA Banque Pictet & Cie SA Deloitte Audit SARL

Bank Pictet & Cie (Europe) AG, Succursale de Luxembourg

TOP 10 HOLDINGS

	Sector	Weight
NESTLE SA-REG	Consumer Staples	10.7%
ROCHE HOLDING AG-GENUSSCHEIN	Health Care	9.4%
NOVARTIS AG-REG	Health Care	8.3%
CIE FINANCIERE RICHEMO-A REG	Consumer Discretionary	5.6%
ZURICH INSURANCE GROUP AG	Financials	4.5%
LONZA GROUP AG-REG	Health Care	4.3%
GALDERMA GROUP AG	Health Care	3.7%
GIVAUDAN-REG	Materials	3.6%
BELIMO HOLDING AG-REG	Industrials	3.6%
GEBERIT AG-REG	Industrials	3.6%
Total	·	57.4%
Total number of Holdings		25

CONTACT

BRUELLAN SA Rue Pécolat 1 CH-1201 Genève Tél: +41 22 817 18 55 bam@bruellan.ch

Disclaimer. Bruellan SA has a FINMA authorisation as a collective asset manager. This publication is a promotional document within the meaning of art. 68 LSFin, it is not independent research. It is solely intended to provide information on the funds in question and does not constitute an offer to buy or sell, investment advice or a recommendation regarding investment or other decisions. The funds may be subject to sales restrictions applicable to certain countries or individuals. It is the responsibility of each investor to be aware of the terms and conditions applicable to each product. This publication is directed only at persons authorised to receive it under the regulations in force in their country of domicile.

The information contained herein is based on sources believed to be reliable. This is a marketing communication. Bruellan cannot guarantee its completeness and accuracy and accepts no liability for any damage that may result from actions taken on the basis of the information published in this document. The information reflects the situation on the day of publication. We have classified this product as 5 out of 7, which is a medium - high risk class. Please refer to the prospectus for more information on the specific risks relevant to this product not included in the summary indicator.

Investment decisions should always be made on the basis of a detailed source of information, in particular the fund prospectus. The prospectus, the articles of association, the key information document, the subscription form and the latest annual and semi-annual reports can be obtained (free of charge) from the Swiss representative, Fund Partner Solutions (Suisse) SA, 60, route des Acacias, 1211 Geneva. Please refer to the prospectus and information document of the fund before making any final investment decisions. You can obtain a summary of investors rights to the following link: https://www.pictet.com/content/dam/www/documents/legal-and-notes/fundpartner-solutions/fps-summary-of-Investors-rights.pdf. The decision to invest in the promoted fund should take into account all the characteristics or objectives of the promoted fund as described in its prospectus. Information on sustainability-related aspects provided in relation to the promoted fund could be found on the following link: https://assetservices.group.pictet/asset-services/esg-disclosures?isin=LU1118008553. Incorporation of extra-financial risks into the investment decision process may result in underweighting of profitable investments from the sub-fund's investment universe and may also lead the management of the sub-fund to underweight investments that will continue to perform. The Fund has been classified as a financial product subject to Article 8 of Regulation (EU)